Skip to main content

Table 2 Differences in demographic, clinical and laboratory parameters and pharmacological treatment between SoC and Intensive therapy group at end of intervention

From: Efficacy and durability of multifactorial intervention on mortality and MACEs: a randomized clinical trial in type-2 diabetic kidney disease

Parameter End of treatment  
SoC Group (n = 169) Intervention group (n = 199) p**
Systolic blood pressure (mmHg) 135.1 (15.2) 127.3 (8.7) 0.004
Diastolic blood pressure (mmHg) 78.8 (8.8) 78.1 (5.6) 0.110
 BP < 130/80 mmHg (%) 132 (74.2) 163 (84.5) 0.045
Laboratory tests    
eGFR EPI-CKD (mL/min) 60.7 (22.9) 60.4 (22.5) 0.920
Albuminuria (mg/day) 90.2 (38–160) 54 (11–180) 0.179
 Albuminuria < 30 mg/day (%) 18 (13.0) 62 (37.6) 0.047
Fasting plasma glucose (mg/dL) 153.6 (44.8) 147.4 (39.4) 0.199
HbA1c (%) 7.4 (1.1) 6.9 (0.6) 0.009
 HbA1c < 7% (%) 88 (52.1) 129 (64.8) 0.133
Total cholesterol (mg/dL) 190.9 (33) 173 (28.9) 0.015
Total cholesterol < 175 mg/dL (%) 55 (32.5) 106 (53.2) 0.054
LDL cholesterol (mg/dL) 122.3 (29.8) 100.5 (26.5)  < 0.001
LDL < 100 mg/dL (%) 34 (20.1) 106 (53.2) 0.001
Triglycerides (mg/dL), median (IQR) 122 (90–171) 145 (120–169) 0.794
Therapy    
 Anti-hypertensive drugs, median (IQR) 1 (1–3) 2 (1–3)  < 0.001
ACEi/ARBs, No. (%)    
 ACEi 104 (61.8) 7 (3.4)  
 ARBs 56 (33.1) 5 (2.3)  
 ACE + ARBs 3 (1.8) 187 (94.3)  
 None 6 (3.6)  < 0.001
Diuretics, No. (%) 84 (49.7) 113 (56.8) 0.864
Calcium channel Blockers, No. (%) 59 (34.9) 79 (39.7) 0.687
Beta-blockers, No. (%) 30 (17.8) 38 (19.1) 0.961
Alpha-blockers, No. (%) 6 (3.6) 10 (4.8) 0.574
Diabetes therapy, No. (%)    0.843
 Diet 5 (2.9) 5 (2.5)  
 Insulin 57 (33.7) 73 (36.7)  
 Oral anti-hyperglycemics 77 (45.6) 88 (44.2)  
 Combined therapy 16 (9.5) 25 (12.6)  
 Missing 14 (8.3) 8 (4)  
Use of statins, No. (%) 84 (49.7) 110 (55.3) 0.991
Use of antiplatelets, No. (%) 104 (61.6) 148 (74.4) 0.905
  1. Data are mean (SD) or median [IQR]
  2. P Blood Pressure, GFR Glomerular Filtration rate, HbA1c glycated haemoglobin, ACEi Angiotensin-Converting-Enzyme inhibitor, ARB Angiotensin II receptor blockers
  3. ** P values refer to difference between SoC and Intensive therapy at the end of treatment and were computed by generalized estimating equations (GEE) model with cluster as group and adjusted with baseline value as covariate